For example, the C5aR1 antagonist avacopan (AVA, ChemoCentryx, Mountain View, CA) has shown therapeutic efficacy in ANCA-associated vasculitis in a phase III clinical study, supporting the utility of C5aR1 antagonists in human disease (20). The gene discussed is C5AR1; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.